Navigation Links
Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
Date:7/31/2008

EMERYVILLE, Calif., July 31 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Bank of America 2008 Specialty Pharmaceuticals Conference on Thursday, August 7, at 3:05 p.m. Eastern Time. Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/wt/page/event_calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through September 7, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
2. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
3. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
7. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
8. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
11. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... The Council for Agricultural Science and ... CAST Communication Award goes to Dr. Channapatna Prakash, ... Alabama. Award nominees must demonstrate an ability to ... use of television, radio, or other social media. ... specialist in the field of plant genetics and ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, ... announced its U.S. joint venture with G-treeBNT (ReGenTree ... phase 3 clinical trial for the orphan disorder, ... trial for dry eye syndrome (DES) in the ... eye drops, RGN-259/GBT201, this year.  Each of these ...
(Date:4/16/2015)... 16, 2015 A new infographic compiles ... for research institutions to learn how Appleā€™s new framework ... The timing is ideal since Apple made Research ... is an open-source framework for developing medical research apps ... way for researchers to collect secure clinical data and ...
(Date:4/16/2015)... -- Avelas Biosciences, an in vivo cancer ... that it has initiated a Phase 1b study of ... primary, non-recurrent breast cancer undergoing surgery. In commencing the ... Steven Chen , M.D., as vice president of ... study will enroll up to 39 women with stage ...
Breaking Biology Technology:The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... K. Gwathmey VMD, Ph.D., FACC,FAHA has served as ... for twelve years. Gwathmey, Inc. is an internationally,recognized ... lead compounds prior to their conversion into marketable ... campaign with other members of the,quiet rural community ...
... MILWAUKEE, March 10 Elekta Neuromag(R), the,world-leading ... Magnetoencephalography (MEG) technology, has been ordered by,Froedtert ... ), Located in the western ... critical role in the quality of life ...
... The Netherlands, March 10 Two clinical,psychologists ... in,Holland, Jaap Hollander and Jeffrey Wijnberg, have ... is an online computer,program that helps people ... the,unique quality, as compared with other on ...
Cached Biology Technology:Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in Milwaukee 2Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in Milwaukee 3Robot Psychologist: A New Era in Mental Health Services With MindMentor 2
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Biometrics - Global Strategic Business Report" report to their ... Iris Biometrics in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Latin America . Annual ...
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... hydrothermal ventsmore than a mile below the ocean ... stomach,they stand rooted to one spot. Fornourishment, they ... to metabolize the sulphurous volcanicsoup in which they ... these giantsare born bacteria-free, with a completedigestive system. ...
... In times of plenty, the uni-cellular slime mold Dictyostelium ... the forest floor. But these simple creatures can perform ... up, Dictyostelium amebas band together with their neighbors and ... , In a forthcoming study in Nature Chemical Biology, ...
... smoke during pregnancy can develop hearing-related cognitive deficits. For ... not only implicates nicotine as the culprit, but also ... cause these deficits. , In a study using ... and colleagues from UC Irvine, showed that nicotine exposure ...
Cached Biology News:Giant deep-sea tubeworm's meal ticket comes in as a skin infection 2Giant deep-sea tubeworm's meal ticket comes in as a skin infection 3When the going gets tough, slime molds start synthesizing 2When the going gets tough, slime molds start synthesizing 3When the going gets tough, slime molds start synthesizing 4Nicotine exposure during development leads to hearing problems 2Nicotine exposure during development leads to hearing problems 3
... The product contains 5 ml Dynabeads ... with glycidyl ether (epoxy) reactive groups. Ideal ... Proteins are absorbed hydrophobically on initial coupling ... (NH 2 and sulphydryll groups (SH)) ...
... Normal;heading 1;heading ... types and experimental ... for standard transfection ... transduction systems. ViraPower ...
...
Mouse Anti-Gemin2...
Biology Products: